Quick Answer
Immunovant, Inc. reported Earnings Per Share Diluted of $2.73 (loss) per share for the year ending 2025.
- Immunovant, Inc. showed a decrease of -45.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Immunovant, Inc.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.38 (loss) per share | Q3 2020: $0.25 (loss) per share | Q4 2020: $0.32 (loss) per share | Q2 2021: $0.31 (loss) per share | Q3 2021: $0.35 (loss) per share | Q4 2021: $0.36 (loss) per share | Q2 2022: $0.35 (loss) per share | Q3 2022: $0.41 (loss) per share | Q4 2022: $0.49 (loss) per share | Q2 2023: $0.57 (loss) per share | Q3 2023: $0.45 (loss) per share | Q4 2023: $0.36 (loss) per share | Q2 2024: $0.60 (loss) per share | Q3 2024: $0.74 (loss) per share | Q4 2024: $0.76 (loss) per share | Q2 2025: $0.71 (loss) per share | Q3 2025: $0.73 (loss) per share | Q4 2025: $0.61 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Immunovant, Inc.'s Earnings Per Share Diluted has declined by 123.8%.
- Historical annual values: Fiscal year 2025: $2.73 (loss) per share | Fiscal year 2024: $1.88 (loss) per share | Fiscal year 2023: $1.71 (loss) per share | Fiscal year 2022: $1.43 (loss) per share | Fiscal year 2021: $1.22 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: